Adoptive cell therapy (ACT) is a type of cancer treatment that involves using a patient's own immune cells to target and attack cancer cells. The ACT market is expected to grow rapidly in the coming years due to the increasing prevalence of cancer and the promising results from ongoing clinical trials. The market is driven by factors such as the increasing adoption of personalized medicine, the growing demand for targeted and effective cancer therapies, and the emergence of new technologies and techniques for cell engineering. However, the high cost of ACT, technical challenges in manufacturing and delivering cell therapies, and regulatory hurdles may pose challenges to the growth of the market. Nonetheless, the potential benefits of ACT are significant, making it an exciting and rapidly evolving field.
The Global Adoptive Cell Therapy Market is estimated to be valued at US$ 4,932.5 million in 2022 and is expected to exhibit a CAGR of 21.5% during the forecast period (2022-2030).
Market Players in the Adoptive Cell Therapy Industry:
Novartis AG
Founded in 1996, Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. The company operates in over 150 countries and has a workforce of over 100,000 employees. Novartis AG is a leading player in the pharmaceutical industry, with a focus on innovative medicines, generics, biosimilars, and eye care. In March, 2023 Sandoz, the global leader in off-patent medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas.
Gilead Sciences, Inc.
Founded in 1987, Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California. The company operates in over 35 countries and employs over 13,000 people. Gilead Sciences, Inc. is known for its focus on antiviral drugs, including treatments for HIV, hepatitis B and C, and influenza. On January, 2023 Kite, a Gilead Company and Arcellx, Inc. announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.
Castle Creek Biosciences, Inc.
Founded in 2015, Castle Creek Biosciences, Inc. is a US-based biopharmaceutical company headquartered in Exton, Pennsylvania. The company focuses on developing therapies for rare and serious dermatologic conditions. Castle Creek Biosciences, Inc. operates primarily in the United States. In January, 2022 Castle Creek Biosciences, Inc., announced it has acquired Novavita Thera, Inc., a preclinical gene therapy company focused on rare liver and metabolic diseases.